Facebook
X
LinkedIn
Forward2026 Advances in Glomerular and Rare Kidney Diseases Conference
Join nephrology experts to discuss recent advances and emerging therapeutic strategies in the management of glomerular and rare kidney diseases. Topics will include advances in disease mechanisms, novel immunologic and complement-mediated therapies, genetic testing in kidney disease, and evolving treatment approaches for conditions such as C3 glomerulopathy, IgA nephropathy, membranous nephropathy, ANCA associated vasculitis and other rare glomerular disorders. The program will emphasize the integration of new evidence into clinical practice, improving diagnostic precision, and optimizing patient outcomes through interprofessional and personalized approaches to care.
Intended Audience
This conference is designed for physicians, nurse practitioners, physician assistants, pharmacists, nurses, and other health professionals involved in the care of patients with kidney diseases.
Elements of Competence
This activity has been designed to change learner competence and focuses on the following competencies:
Accreditation Council for Graduate Medical Education (ACGME)/NURSING: Patient care and procedural skills and Medical knowledge
Interprofessional Education Collaborative Competencies: Roles and responsibilities
Center for the Advancement of Pharmacy Education (CAPE): Foundational knowledge
Pharmacy Technician Certification Board (PTCB): Medications
Learning Objectives
As a result of participation in this educational activity, the healthcare team will be able to:
Diagnose rare kidney diseases and glomerular disorders.
Apply current evidence and emerging therapies to patient care.
Identify patients who may benefit from referral to specialized programs and clinical trials.
Adopt team-based approaches when caring for patients with rare kidney diseases and glomerular disorders.
Agenda - Thursday August 13, 2026
Start Time | Session, Room Location, and Speaker(s) |
|---|---|
| 12:00 p.m. | Registration/Lunch/Exhibitors (HSLC 1220 – 1222) |
| 12:30 p.m. | Welcome Remarks (HSLC 1335) |
| 12:35 p.m. | Four Pillars of a Complete Evaluation (HSLC 1335) |
| 1:30 p.m. | AAV: Advances in Diagnosis and Therapeutics (HSLC 1335) |
| 2:15 p.m. | Break/Snack/Exhibitors (HSLC 1220 – 1222) |
| 2:40 p.m. | Current and Novel Therapies in FSGS (HSLC 1335) |
| 3:25 p.m. | C3 Glomerulonephritis: Diagnosis and Management (HSLC 1335) |
| 4:10 p.m. | Interactive Session (HSLC 1335) |
| 4:55 p.m. | Closing Remarks (HSLC 1335) |
Planning Committee
Co-Chairs:
Fahad Aziz, MD, Honorary Associate/Fellow, Associate Professor (CHS), Department of Medicine, Division of Nephrology, University of Wisconsin School of Medicine and Public Health
Tripti Singh, MD, Associate Professor (CHS), Department of Medicine, Division of Nephrology, University of Wisconsin School of Medicine and Public Health
Committee Members:
Margaret Jorgenson, PharmD, BCTXP, Clinical Pharmacist, UW Health
Brittany Olson, NP, Nurse Practitioner - Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health
Amanda Weber, RN, Clinical Supervisor - UW Health
Conference Faculty
Richard Smith, MD, Professor, Director, Molecular Otolaryngology and Renal Research Laboratories, Carver College of Medicine, University of Iowa
Sarah Panzer, MD, Associate Professor (CHS), Department of Medicine, Division of Nephrology, University of Wisconsin School of Medicine and Public Health
It is the policy of the University of Wisconsin–Madison Inter-professional Continuing Education Partnership (ICEP) to identify, mitigate and disclose all relevant financial relationships with ineligible companies* held by the speakers/presenters, authors, planners, and other persons who may influence the content of this accredited continuing education (CE). In addition, speakers, presenters and authors must disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentation.
For this accredited continuing education activity all relevant financial relationships have been mitigated and detailed disclosures are listed below.
Name | Role | Financial Relationship Disclosures | Discussion of Unlabeled/Unapproved uses of drugs/devices in presentation? |
*Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on, patients. The ACCME does not consider providers of clinical services directly to patients to be ineligible companies.
Accreditation and Credit Designation Statements
Joint Accreditation Logo | UW-Madison ICEP Accreditation Statement |
 | In support of improving patient care, the University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. |
Credit Designation Logos | Credit Designation Statements |
American Medical Association (AMA) The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. | |
American Nurses Credentialing Center (ANCC) The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 4.0 ANCC contact hours, | |
 | American Academy of Physician Assistants (AAPA) The University of Wisconsin–Madison ICEP has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 4.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. |
Accreditation Council for Pharmacy Education (ACPE) The University of Wisconsin–Madison ICEP designates this knowledge-based activity for a maximum of 4.0 hours or 0.4 CEUs. Credit can be earned by documented attendance. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion. | |
 | American Board of Internal Medicine MOC Credit American Board of Internal Medicine: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
| Continuing Education Units (CEUs) The University of Wisconsin–Madison ICEP, as a member of the University Professional & Continuing Education Association (UPCEA), authorizes this program for 0.4 continuing education units (CEUs) or 4.0 hours. |
Available Credit
- 4.00 AAPA Category 1 CME
- 4.00 MOC: ABIM Medical Knowledge Points (Part II)
- 4.00 ACPE Contact Hours - Pharmacist
- 4.00 AMA PRA Category 1 Credit™
- 4.00 ANCC Contact Hours
- 0.00 ANCC Pharmacotherapy Contact Hours
- 4.00 University of Wisconsin–Madison Continuing Education Hours
- 4.00 Approved for AMA PRA Category 1 Credit™
Exhibitors
Amgen
Novartis
Otsuka
Travere Therapeutics
Vertex Pharmaceuticals
Conference Fees
There is no fee to attend this conference.
Registration for this activity can only be completed through the ICEP Learning Portal. Attendee registrations made through any other sites cannot be honored. UW-Madison ICEP is not able to refund fees paid through unaffiliated registration sites, such as eMedEvents.com, MedConfWorld.com, EventEgg.com, and 10times.com. Please report any unauthorized websites or solicitations for registrations to [email protected].
Cancellation Policy
Requests for cancellation must be submitted in writing to [email protected].
Questions about Registration
Email [email protected]
Program Changes
Emergency situations occasionally occur and may necessitate topic or speaker changes. The University of Wisconsin–Madison ICEP reserves the right to alter or substitute a topic or speaker without prior notification.
Accessibility
We value inclusion and access for all participants and are pleased to provide reasonable accommodation for this event. Please contact [email protected] as soon as you can make a reasonable accommodation request.
Additional Information
For conference information or details regarding exhibit booths please contact Adam Flyte at [email protected].